Effects of nebivolol or irbesartan in combination with hydrochlorothiazide on vascular functions in newly-diagnosed hypertensive patients: The NINFE (Nebivololo, Irbesartan Nella Funzione Endoteliale) study

International Journal of Cardiology

Volumn 155, Issue 2, 2012, Pages 279-284

  Vitale, Cristiana ^a   Marazzi, Giuseppe ^a   Iellamo, Ferdinando ^a,b   Spoletini, Ilaria ^a   Dall'Armi, Valentina ^a   Fini, Massimo ^a   Volterrani, Maurizio ^a  

^a IRCCS SAN RAFFAELE PISANA   (Italy)

^b UNIVERSITY OF ROME TOR VERGATA   (Italy)

Author keywords

Arterial hypertension; AT1 receptor antagonists; Beta blockers; Central blood pressure; Endothelial function; Pulse wave velocity

Indexed keywords

HYDROCHLOROTHIAZIDE; HYDROCHLOROTHIAZIDE PLUS IRBESARTAN; IRBESARTAN; NEBIVOLOL; NEBIVOLOL PLUS HYDROCHLOROTHIAZIDE; UNCLASSIFIED DRUG;

ADULT; ANKLE BRACHIAL INDEX; ARTERIAL STIFFNESS; ARTICLE; AUGMENTATION INDEX; BLOOD PRESSURE MEASUREMENT; BLOOD PRESSURE REGULATION; BRADYCARDIA; COMBINATION CHEMOTHERAPY; CONTROLLED STUDY; DIASTOLIC BLOOD PRESSURE; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG WITHDRAWAL; FEMALE; HEART HEMODYNAMICS; HEART RATE; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALAISE; MALE; PATIENT COMPLIANCE; PRIORITY JOURNAL; PULSE WAVE; RANDOMIZED CONTROLLED TRIAL; SHORT COURSE THERAPY; SYSTOLIC BLOOD PRESSURE;

ADRENERGIC BETA-1 RECEPTOR ANTAGONISTS; ADULT; ANGIOTENSIN II TYPE 1 RECEPTOR BLOCKERS; BENZOPYRANS; BIPHENYL COMPOUNDS; BLOOD FLOW VELOCITY; BLOOD PRESSURE; DIURETICS; DRUG THERAPY, COMBINATION; ENDOTHELIUM, VASCULAR; ETHANOLAMINES; FEMALE; HUMANS; HYDROCHLOROTHIAZIDE; HYPERTENSION; MALE; MIDDLE AGED; PULSATILE FLOW; TETRAZOLES; TREATMENT OUTCOME; VASCULAR STIFFNESS;

EID: 84857045177     PISSN: 01675273     EISSN: 18741754     Source Type: Journal    
DOI: 10.1016/j.ijcard.2011.10.099     Document Type: Article

References (45)

1. A. Adji, M.F. O'Rourke, and M. Namasivayam Arterial stiffness, its assessment, prognostic value, and implications for treatment Am J Hypertens 24 2011 5 17
2. T.J. Anderson Arterial stiffness or endothelial dysfunction as a surrogate marker of vascular risk Can J Cardiol 22 Suppl. B 2006 72B 80B
3. D.J. Green, H. Jones, D. Thijssen, N.T. Cable, and G. Atkinson Flow-mediated dilation and cardiovascular event prediction: does nitric oxide matter? Hypertension 57 2011 363 369
4. U. Landmesser, B. Hornig, and H. Drexler Endothelial function: a critical determinant in atherosclerosis? Circulation 109 2004 II27 II33
5. R. Rubinshtein, J.T. Kuvin, and M. Soffler Assessment of endothelial function by non-invasive peripheral arterial tonometry predicts late cardiovascular adverse events Eur Heart J 31 2011 1142 1148
6. C. Vlachopoulos, K. Aznaouridis, M.F. O'Rourke, M.E. Safar, K. Baou, and C. Stefanadis Prediction of cardiovascular events and all-cause mortality with central haemodynamics: a systematic review and meta-analysis Eur Heart J 31 2011 1865 1871
7. C. Vlachopoulos, K. Aznaouridis, and C. Stefanadis Prediction of cardiovascular events and all-cause mortality with arterial stiffness: a systematic review and meta-analysis J Am Coll Cardiol 55 2011 1318 1327
8. M.E. Widlansky, N. Gokce, J.F. Keaney Jr., and J.A. Vita The clinical implications of endothelial dysfunction J Am Coll Cardiol 42 2003 1149 1160
9. E. Agabiti-Rosei, G. Mancia, and M.F. O'Rourke Central blood pressure measurements and antihypertensive therapy: a consensus document Hypertension 50 2007 154 160
10. T. Morgan, J. Lauri, D. Bertram, and A. Anderson Effect of different antihypertensive drug classes on central aortic pressure Am J Hypertens 17 2004 118 123
11. E. Bragulat, M. Larrousse, A. Coca, and A. de la Sierra Effect of long-term irbesartan treatment on endothelium-dependent vasodilation in essential hypertensive patients Br J Biomed Sci 60 2003 191 196
12. B. von zur Muhlen, T. Kahan, A. Hagg, J. Millgard, and L. Lind Treatment with irbesartan or atenolol improves endothelial function in essential hypertension J Hypertens 19 2001 1813 1818
13. M.P. Schneider, C. Delles, and A.U. Klingbeil Effect of angiotensin receptor blockade on central haemodynamics in essential hypertension: results of a randomised trial J Renin Angiotensin Aldosterone Syst 9 2008 49 56
14. E.J. Lewis, L.G. Hunsicker, and W.R. Clarke Renoprotective effect of the angiotensin-receptor antagonist irbesartan in patients with nephropathy due to type 2 diabetes N Engl J Med 345 2001 851 860
15. B. Dahlof, R.B. Devereux, and S.E. Kjeldsen Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE): a randomised trial against atenolol Lancet 359 2002 995 1003
16. S. Julius, S.E. Kjeldsen, and M. Weber Outcomes in hypertensive patients at high cardiovascular risk treated with regimens based on valsartan or amlodipine: the VALUE randomised trial Lancet 363 2004 2022 2031
17. P. Verdecchia, P. Sleight, and G. Mancia Effects of telmisartan, ramipril, and their combination on left ventricular hypertrophy in individuals at high vascular risk in the Ongoing Telmisartan Alone and in Combination with Ramipril Global End Point Trial and the Telmisartan Randomized Assessment Study in ACE intolerant subjects with cardiovascular disease Circulation 120 2009 1380 1389
18. L.H. Lindholm, B. Carlberg, and O. Samuelsson Should beta blockers remain first choice in the treatment of primary hypertension? A meta-analysis Lancet 366 2005 1545 1553
19. W.S. Aronow Current role of beta-blockers in the treatment of hypertension Expert Opin Pharmacother 11 2011 2599 2607
20. C.V. Ram Beta-blockers in hypertension Am J Cardiol 106 2011 1819 1825
21. O. Kamp, M. Metra, and S. Bugatti Nebivolol: haemodynamic effects and clinical significance of combined beta-blockade and nitric oxide release Drugs 70 2011 41 56
22. T. Munzel, and T. Gori Nebivolol: the somewhat-different beta-adrenergic receptor blocker J Am Coll Cardiol 54 2009 1491 1499
23. N. Tzemos, P.O. Lim, and T.M. MacDonald Nebivolol reverses endothelial dysfunction in essential hypertension: a randomized, double-blind, crossover study Circulation 104 2001 511 514
24. G. Mancia, G. De Backer, and A. Dominiczak 2007 guidelines for the management of arterial hypertension: The Task Force for the Management of Arterial Hypertension of the European Society of Hypertension (ESH) and of the European Society of Cardiology (ESC) Eur Heart J 28 2007 1462 1536
25. M.S. Zhou, I.H. Schulman, E.A. Jaimes, and L. Raij Thiazide diuretics, endothelial function, and vascular oxidative stress J Hypertens 26 2008 494 500
26. K.K. Koh, M.J. Quon, and S.H. Han Distinct vascular and metabolic effects of different classes of anti-hypertensive drugs Int J Cardiol 140 2011 73 81
27. R.M. Conroy, K. Pyorala, and A.P. Fitzgerald Estimation of ten-year risk of fatal cardiovascular disease in Europe: the SCORE project Eur Heart J 24 2003 987 1003
28. N.M. Hamburg, and E.J. Benjamin Assessment of endothelial function using digital pulse amplitude tonometry Trends Cardiovasc Med 19 2009 6 11
29. J.T. Kuvin, A.R. Patel, and K.A. Sliney Assessment of peripheral vascular endothelial function with finger arterial pulse wave amplitude Am Heart J 146 2003 168 174
30. N.M. Hamburg, M.J. Keyes, and M.G. Larson Cross-sectional relations of digital vascular function to cardiovascular risk factors in the Framingham Heart Study Circulation 117 2008 2467 2474
31. S. Laurent, J. Cockcroft, and L. Van Bortel Expert consensus document on arterial stiffness: methodological issues and clinical applications Eur Heart J 27 2006 2588 2605
32. C.H. Chen, E. Nevo, and B. Fetics Estimation of central aortic pressure waveform by mathematical transformation of radial tonometry pressure. Validation of generalized transfer function Circulation 95 1997 1827 1836
33. I.B. Wilkinson, H. MacCallum, L. Flint, J.R. Cockcroft, D.E. Newby, and D.J. Webb The influence of heart rate on augmentation index and central arterial pressure in humans J Physiol 525 Pt 1 2000 263 270
34. A. Aversa, C. Vitale, and M. Volterrani Chronic administration of Sildenafil improves markers of endothelial function in men with type 2 diabetes Diabet Med 25 2008 37 44
35. S. Bangalore, F.H. Messerli, J.B. Kostis, and C.J. Pepine Cardiovascular protection using beta-blockers: a critical review of the evidence J Am Coll Cardiol 50 2007 563 572
36. B. Williams, P.S. Lacy, and S.M. Thom Differential impact of blood pressure-lowering drugs on central aortic pressure and clinical outcomes: principal results of the Conduit Artery Function Evaluation (CAFE) study Circulation 113 2006 1213 1225
37. P. Kampus, M. Serg, and J. Kals Differential effects of nebivolol and metoprolol on central aortic pressure and left ventricular wall thickness Hypertension 57 2011 1122 1128
38. M.E. Pedersen, and J.R. Cockcroft The vasodilatory beta-blockers Curr Hypertens Rep 9 2007 269 277
39. D.S. Celermajer Reliable endothelial function testing: at our fingertips? Circulation 117 2008 2428 2430
40. J. Lekakis, P. Abraham, and A. Balbarini Methods for evaluating endothelial function: a position statement from the European Society of Cardiology Working Group on Peripheral Circulation Eur J Cardiovasc Prev Rehabil 2011
41. N. Gokce Clinical assessment of endothelial function: ready for prime time? Circ Cardiovasc Imaging 4 2011 348 350
42. N.M. Hamburg, J. Palmisano, and M.G. Larson Relation of brachial and digital measures of vascular function in the community: the Framingham heart study Hypertension 57 2011 390 396
43. A. Nohria, M. Gerhard-Herman, M.A. Creager, S. Hurley, D. Mitra, and P. Ganz Role of nitric oxide in the regulation of digital pulse volume amplitude in humans J Appl Physiol 101 2006 545 548
44. P. Greenland, J.S. Alpert, and G.A. Beller 2010 ACCF/AHA guideline for assessment of cardiovascular risk in asymptomatic adults: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 56 2011 e50 e103
45. L.G. Shewan, and A.J. Coats Ethics in the authorship and publishing of scientific articles Int J Cardiol 144 2010 1 2